CancerVax vaccine (CANVAXIN)
Phase 3Vaccine
CancerVax vaccine (CANVAXIN) is one of 36 biologic programs targeting Melanoma. It is currently in Phase 3.
1
Indications
2
Total Trials
0
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
947 competitors in Melanoma
#DrugCompanyPhaseTrials
1Tecentriq
RochePhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Roferon-a
RochePhase 3
CC 5013
Bristol-Myers SquibbPhase 3
Methylphenidate Hydrochloride
TakedaPhase 3
Adjuvant Therapy
FFudan University
Phase 3
Bempegaldesleukin
NNektar Therapeutics
Phase 3
Interferon-Alpha-2a
RochePhase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Preclinical
CancerVax vaccine (CANVAXIN)
CCancerVax Corporation
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Vaccine[2]
- Highest Phase
- Phase 3[1]
- Company
- CCancerVax Corporation